



FINANCIAL TEAR SHEET

CORPORATE PROFILE


Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

STOCK INFORMATION

CHRS (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$19.40
Change (%)	▲ 0.65 (3.47%)
Volume	313,814
52 Week Low	\$8.05
Market Cap	\$1,315,724,044
Rolling EPS	-3.30
PE Ratio	N/A
Shares Outstanding	67,820,827

Data as of 08/14/18 4:00 p.m. ET



RECENT NEWS & UPCOMING EVENTS

08/08/18

[Coherus BioSciences Reports Corporate Highlights and Second Quarter 2018 Financial Results](#)

07/27/18

[Coherus BioSciences Receives Positive CHMP Opinion for UDENYCA™ \(Pegfilgrastim Biosimilar Candidate\)](#)

07/25/18

[Coherus BioSciences Announces New Employment Inducement Grants](#)

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
08/08/18	<u>10-Q</u>
08/08/18	<u>8-K</u>
07/31/18	<u>8-K</u>
07/25/18	<u>4</u>

CORPORATE GOVERNANCE

<u>Denny Lanfear</u>	President, CEO and Chairman
<u>Barbara Finck, M.D.</u>	Chief Medical Officer
<u>Alan Herman, Ph.D.</u>	Chief Scientific Officer
<u>Jean-Frederic Viret, Ph.D.</u>	Chief Financial Officer
<u>Peter Watler, Ph.D.</u>	Chief Technical Officer
<u>Vince Anicetti</u>	SVP, Global Quality
<u>Lisa M. Bell, Ph.D.</u>	SVP, Regulatory Affairs
<u>Michael Fleming</u>	SVP, Commercial Strategy
<u>Matthew R. Hooper</u>	SVP, General Counsel

Data provided by Nasdaq. Minimum 15 minutes delayed.